MeSH term
Frequency | Condition_Probility | Albumins/metabolism | 2 | 1.0 |
Albuminuria/*prevention & control | 2 | 2.0 |
Antihypertensive Agents/*therapeutic use | 2 | 0.0 |
Diabetes Mellitus, Type 2/complications/*drug therapy | 2 | 2.0 |
Humans | 1049 | 0.0 |
Hypertension/complications/*drug therapy | 2 | 1.0 |
Indoles/*therapeutic use | 2 | 1.0 |
Renin-Angiotensin System/*drug effects | 2 | 1.0 |
Adult | 374 | 0.0 |
Aged | 271 | 0.0 |
Breast Neoplasms/*genetics | 257 | 32.0 |
Carcinoma, Intraductal, Noninfiltrating/*genetics | 3 | 60.0 |
Female | 831 | 0.0 |
*Genes, BRCA1 | 223 | 43.0 |
*Genes, BRCA2 | 159 | 68.0 |
Middle Aged | 383 | 0.0 |
Mutation | 183 | 2.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 95 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 265 | 0.0 |
Diagnosis, Differential | 2 | 0.0 |
BRCA1 Protein/*genetics | 93 | 43.0 |
BRCA2 Protein/*genetics | 54 | 72.0 |
DNA Mutational Analysis | 113 | 2.0 |
DNA, Neoplasm/chemistry/genetics | 14 | 11.0 |
Family Health | 55 | 5.0 |
Incidence | 41 | 3.0 |
Research Support, Non-U.S. Gov't | 589 | 0.0 |
Turkey/epidemiology | 2 | 2.0 |
Breast Neoplasms/epidemiology/*genetics | 46 | 37.0 |
Genetic Counseling/*methods | 4 | 44.0 |
*Genetic Predisposition to Disease | 65 | 6.0 |
Genetic Screening/methods | 10 | 8.0 |
Heterozygote | 77 | 2.0 |
Ovarian Neoplasms/epidemiology/*genetics | 26 | 37.0 |
Patient Education | 3 | 5.0 |
Prevalence | 30 | 2.0 |
Risk Assessment | 54 | 6.0 |
Risk Factors | 167 | 2.0 |
Sensitivity and Specificity | 18 | 0.0 |
Age of Onset | 65 | 5.0 |
Codon, Nonsense | 4 | 2.0 |
Comparative Study | 75 | 0.0 |
DNA, Neoplasm/genetics | 28 | 3.0 |
Exons/genetics | 24 | 1.0 |
Frameshift Mutation | 21 | 5.0 |
Genetic Predisposition to Disease | 138 | 5.0 |
*Germ-Line Mutation | 74 | 17.0 |
Great Britain/epidemiology | 7 | 6.0 |
Molecular Sequence Data | 80 | 0.0 |
Mutation, Missense | 13 | 1.0 |
Neoplastic Syndromes, Hereditary/epidemiology/*genetics | 10 | 50.0 |
Polymerase Chain Reaction | 83 | 0.0 |
Polymorphism, Genetic | 27 | 0.0 |
Polymorphism, Single-Stranded Conformational | 45 | 2.0 |
Aged, 80 and over | 98 | 1.0 |
DNA-Binding Proteins/genetics | 12 | 1.0 |
*Genes, Tumor Suppressor | 36 | 3.0 |
Male | 273 | 0.0 |
Pancreatic Neoplasms/*genetics | 9 | 10.0 |
Pedigree | 150 | 2.0 |
Trans-Activators/genetics | 2 | 0.0 |
DNA Primers/chemistry | 7 | 0.0 |
Gene Expression Profiling | 3 | 0.0 |
Gene Expression Regulation, Neoplastic | 23 | 1.0 |
Genotype | 53 | 0.0 |
Germ-Line Mutation | 70 | 17.0 |
Oligonucleotide Array Sequence Analysis | 5 | 0.0 |
Ovarian Neoplasms/*genetics/metabolism | 5 | 13.0 |
RNA, Messenger/analysis/genetics | 3 | 0.0 |
RNA, Neoplasm/analysis | 3 | 1.0 |
Reverse Transcriptase Polymerase Chain Reaction | 25 | 0.0 |
BRCA1 Protein/*genetics/metabolism | 4 | 19.0 |
BRCA2 Protein/*genetics/metabolism | 5 | 100.0 |
Breast Neoplasms/genetics/metabolism | 4 | 8.0 |
Linkage (Genetics) | 28 | 1.0 |
English Abstract | 43 | 0.0 |
Genes, p16 | 5 | 5.0 |
Genes, p53 | 17 | 3.0 |
Genes, ras | 5 | 2.0 |
Pancreatic Neoplasms/*diagnosis/*genetics | 2 | 40.0 |
Animals | 123 | 0.0 |
Cell Division/genetics | 3 | 0.0 |
Chromosome Aberrations | 17 | 3.0 |
Chromosome Mapping | 38 | 0.0 |
*Chromosomes, Human, Pair 13 | 21 | 12.0 |
Disease Progression | 10 | 0.0 |
Genetic Markers | 71 | 2.0 |
In Situ Hybridization, Fluorescence | 14 | 0.0 |
Kinetics | 3 | 0.0 |
Neoplasm Metastasis | 2 | 0.0 |
*Alternative Splicing | 3 | 0.0 |
Amino Acid Sequence | 42 | 0.0 |
Antibody Specificity | 4 | 0.0 |
Base Sequence | 63 | 0.0 |
Cell Line | 29 | 0.0 |
Cloning, Molecular | 18 | 0.0 |
DNA, Complementary | 5 | 0.0 |
Precipitin Tests | 9 | 0.0 |
Protein Structure, Tertiary | 17 | 0.0 |
Tumor Cells, Cultured | 55 | 0.0 |
DNA Primers | 33 | 0.0 |
False Positive Reactions | 2 | 0.0 |
Homozygote | 8 | 0.0 |
*Polymorphism, Single Nucleotide | 4 | 0.0 |
*Sequence Deletion | 18 | 4.0 |
BRCA1 Protein/metabolism | 10 | 27.0 |
BRCA2 Protein/metabolism | 5 | 100.0 |
DNA Damage | 40 | 4.0 |
DNA Repair | 44 | 6.0 |
Fanconi Anemia/*genetics | 5 | 10.0 |
Mice | 70 | 0.0 |
Mice, Knockout | 12 | 0.0 |
Nuclear Proteins/genetics/metabolism | 4 | 2.0 |
Phenotype | 53 | 0.0 |
Protein-Serine-Threonine Kinases/metabolism | 5 | 0.0 |
Alleles | 46 | 0.0 |
Fibroblasts | 2 | 0.0 |
Gene Silencing | 5 | 1.0 |
Genes, BRCA1 | 98 | 49.0 |
Genetic Complementation Test | 8 | 1.0 |
Mitomycin/pharmacology | 5 | 5.0 |
*Mutation | 121 | 2.0 |
RNA, Messenger/genetics/metabolism | 6 | 0.0 |
Transfection | 12 | 0.0 |
BRCA1 Protein/analysis | 3 | 60.0 |
BRCA2 Protein/analysis | 2 | 100.0 |
Breast/*metabolism | 3 | 5.0 |
Breast Neoplasms/*genetics/metabolism | 15 | 14.0 |
Cell Division/drug effects | 5 | 0.0 |
Chromatography, Affinity | 2 | 0.0 |
Gene Expression/drug effects | 2 | 0.0 |
Genes, BRCA2/*drug effects | 2 | 100.0 |
Polymerase Chain Reaction/methods | 9 | 0.0 |
RNA, Messenger/analysis | 3 | 0.0 |
Breast Neoplasms/ethnology/*genetics | 10 | 50.0 |
Ovarian Neoplasms/ethnology/*genetics | 3 | 33.0 |
Portugal/epidemiology | 2 | 11.0 |
Prospective Studies | 8 | 0.0 |
Spain/epidemiology | 7 | 4.0 |
Breast Neoplasms/diagnosis/*genetics/psychology | 3 | 50.0 |
Cross-Sectional Studies | 3 | 0.0 |
Educational Status | 2 | 3.0 |
Ethnic Groups | 4 | 1.0 |
Genetic Screening/*psychology | 16 | 53.0 |
*Health Knowledge, Attitudes, Practice | 3 | 10.0 |
Questionnaires | 16 | 2.0 |
Breast Neoplasms/epidemiology/*genetics/prevention & control | 6 | 60.0 |
*Decision Making, Computer-Assisted | 2 | 50.0 |
Genetic Screening/*methods | 7 | 4.0 |
Heterozygote Detection | 19 | 3.0 |
Ovarian Neoplasms/epidemiology/*genetics/prevention & control | 6 | 66.0 |
Probability | 12 | 1.0 |
Reproducibility of Results | 16 | 1.0 |
Retrospective Studies | 26 | 0.0 |
United States/epidemiology | 14 | 3.0 |
Oligonucleotide Array Sequence Analysis/*methods | 4 | 3.0 |
RNA, Messenger/biosynthesis/genetics | 2 | 0.0 |
Mutation/genetics | 23 | 2.0 |
Blotting, Western | 10 | 0.0 |
Cell Line, Tumor | 8 | 0.0 |
Radiation Tolerance/*genetics | 5 | 8.0 |
*DNA Damage | 23 | 3.0 |
*DNA Repair | 25 | 3.0 |
Mutagens/*toxicity | 4 | 3.0 |
*Oxidative Stress | 2 | 0.0 |
Breast Neoplasms/diagnosis/*genetics | 14 | 50.0 |
Case-Control Studies | 42 | 0.0 |
Mass Screening | 10 | 5.0 |
Mutation/*genetics | 39 | 3.0 |
Australia/epidemiology | 8 | 12.0 |
Gene Frequency | 35 | 0.0 |
Genes, Dominant | 7 | 0.0 |
Genes, Recessive | 4 | 0.0 |
*Models, Genetic | 8 | 6.0 |
Proportional Hazards Models | 6 | 0.0 |
Cell Nucleus/metabolism | 16 | 0.0 |
Hela Cells | 7 | 0.0 |
Protein Subunits | 2 | 0.0 |
Amino Acid Substitution | 6 | 0.0 |
Breast Neoplasms/etiology/*genetics | 8 | 25.0 |
Cell Survival | 6 | 0.0 |
DNA Repair/*genetics | 14 | 4.0 |
DNA-Binding Proteins/*genetics | 15 | 0.0 |
Jews | 5 | 7.0 |
*Loss of Heterozygosity | 30 | 8.0 |
Breast Neoplasms/genetics | 51 | 23.0 |
In Vitro | 2 | 0.0 |
Radiation Tolerance/genetics | 4 | 8.0 |
*DNA Mutational Analysis | 6 | 3.0 |
DNA, Neoplasm/analysis | 21 | 2.0 |
Neoplastic Syndromes, Hereditary/*genetics | 11 | 26.0 |
Ovarian Neoplasms/*genetics | 112 | 32.0 |
Spain | 6 | 1.0 |
Genes, BRCA1/physiology | 7 | 63.0 |
Genes, BRCA2/physiology | 5 | 55.0 |
Genetic Screening | 87 | 10.0 |
Phosphoric Monoester Hydrolases/genetics | 4 | 5.0 |
Protein p53/genetics | 6 | 3.0 |
Tumor Suppressor Proteins/genetics | 4 | 5.0 |
Breast Neoplasms | 3 | 1.0 |
Cell Cycle | 18 | 1.0 |
Dose-Response Relationship, Drug | 7 | 0.0 |
*Down-Regulation | 2 | 0.0 |
Breast Neoplasms/genetics/*pathology/therapy | 2 | 66.0 |
Combined Modality Therapy | 2 | 0.0 |
Disease-Free Survival | 11 | 1.0 |
Mastectomy, Segmental | 2 | 11.0 |
Neoplasm Recurrence, Local | 3 | 0.0 |
Treatment Outcome | 9 | 0.0 |
*Gene Expression Regulation, Neoplastic | 6 | 0.0 |
Immunohistochemistry | 27 | 0.0 |
Breast Neoplasms/*genetics/*pathology | 7 | 10.0 |
Chi-Square Distribution | 6 | 0.0 |
Immunoenzyme Techniques | 7 | 0.0 |
Immunophenotyping | 4 | 0.0 |
Logistic Models | 17 | 2.0 |
Predictive Value of Tests | 15 | 0.0 |
Antineoplastic Agents, Hormonal/*therapeutic use | 4 | 5.0 |
BRCA1 Protein/genetics | 28 | 43.0 |
BRCA2 Protein/genetics | 20 | 57.0 |
Breast Neoplasms/diagnosis/*genetics/*prevention & control | 2 | 40.0 |
*Genetic Screening | 32 | 16.0 |
Mastectomy | 8 | 11.0 |
Ovariectomy | 11 | 9.0 |
Risk | 37 | 4.0 |
Tamoxifen/*therapeutic use | 4 | 5.0 |
Breast Neoplasms/diagnosis/ethnology/*genetics | 2 | 100.0 |
Canada | 6 | 4.0 |
Family | 24 | 6.0 |
France | 3 | 1.0 |
Ovarian Neoplasms/diagnosis/ethnology/*genetics | 2 | 100.0 |
Age Distribution | 13 | 4.0 |
Genes, BRCA2 | 59 | 57.0 |
Antineoplastic Agents, Hormonal/therapeutic use | 4 | 8.0 |
Contraceptives, Oral, Hormonal/adverse effects | 2 | 15.0 |
Estrogens/metabolism | 5 | 6.0 |
Gene Expression Regulation | 5 | 0.0 |
Genetic Predisposition to Disease/*genetics | 25 | 6.0 |
Tamoxifen/therapeutic use | 6 | 9.0 |
Ataxia Telangiectasia/genetics | 8 | 17.0 |
Breast Neoplasms, Male/etiology/*genetics | 3 | 100.0 |
Genes, p53/*genetics | 5 | 1.0 |
Hamartoma Syndrome, Multiple/genetics | 4 | 25.0 |
Li-Fraumeni Syndrome/genetics | 7 | 43.0 |
Peutz-Jeghers Syndrome/genetics | 2 | 28.0 |
Neoplasm Proteins/*genetics | 273 | 25.0 |
Chromatography, High Pressure Liquid | 3 | 0.0 |
Genetic Predisposition to Disease/genetics | 19 | 4.0 |
Breast Neoplasms, Male/epidemiology/*genetics | 4 | 80.0 |
Chromosomes, Human, Pair 13/genetics | 9 | 13.0 |
Genes, Tumor Suppressor | 33 | 3.0 |
Loss of Heterozygosity | 32 | 3.0 |
*Polymorphism, Genetic | 12 | 0.0 |
Regression Analysis | 4 | 0.0 |
Reproductive History | 2 | 12.0 |
Heterozygote Detection/methods | 4 | 16.0 |
Breast Neoplasms/genetics/*pathology | 9 | 20.0 |
Chromosomes, Human, Pair 17/*genetics | 7 | 4.0 |
*DNA-Binding Proteins | 12 | 0.0 |
Lod Score | 9 | 0.0 |
Microsatellite Repeats | 34 | 2.0 |
Amino Acid Motifs | 5 | 0.0 |
Genetic Diseases, Inborn/genetics | 2 | 4.0 |
Recombination, Genetic | 16 | 1.0 |
Structure-Activity Relationship | 3 | 0.0 |
DNA Mutational Analysis/methods | 7 | 3.0 |
Genetic Counseling | 33 | 19.0 |
Germ-Line Mutation/*genetics | 33 | 21.0 |
Medical History Taking | 3 | 7.0 |
Ontario/epidemiology | 3 | 12.0 |
Registries | 13 | 5.0 |
Breast Neoplasms, Male/genetics | 22 | 56.0 |
Founder Effect | 23 | 17.0 |
Jews/genetics | 28 | 31.0 |
Ovarian Neoplasms/genetics | 57 | 37.0 |
Breast Neoplasms/*genetics/prevention & control | 8 | 44.0 |
Prognosis | 37 | 0.0 |
*Genes, p53 | 15 | 3.0 |
Loss of Heterozygosity/*genetics | 10 | 11.0 |
Sweden/epidemiology | 8 | 7.0 |
Diseases in Twins/*genetics | 3 | 10.0 |
Alternative Splicing | 2 | 0.0 |
DNA Damage/radiation effects | 3 | 13.0 |
DNA Repair/radiation effects | 2 | 15.0 |
Gamma Rays | 4 | 1.0 |
Micronucleus Tests | 2 | 4.0 |
Reference Values | 8 | 0.0 |
Breast Neoplasms/diagnosis/*genetics/therapy | 5 | 62.0 |
Germ-Line Mutation/genetics | 9 | 13.0 |
Japan | 7 | 0.0 |
Aneuploidy | 8 | 4.0 |
BRCA2 Protein/*physiology | 5 | 100.0 |
Cells, Cultured | 8 | 0.0 |
Gene Targeting | 4 | 1.0 |
Mitosis | 13 | 3.0 |
BRCA1 Protein/biosynthesis | 2 | 33.0 |
Breast Neoplasms/*genetics/*metabolism | 6 | 15.0 |
Conserved Sequence | 8 | 0.0 |
*Exons | 4 | 1.0 |
Breast Neoplasms/*diagnosis/genetics | 4 | 22.0 |
BRCA2 Protein/genetics/metabolism | 2 | 40.0 |
Gene Deletion | 19 | 0.0 |
Mammary Neoplasms, Experimental/genetics/pathology | 2 | 28.0 |
Mice, Inbred C57BL | 5 | 0.0 |
Neoplasms, Experimental/*genetics/pathology | 2 | 25.0 |
Breast Neoplasms/diagnosis/genetics | 3 | 27.0 |
Gene Frequency/*genetics | 5 | 3.0 |
Ovarian Neoplasms/diagnosis/genetics | 3 | 33.0 |
Breast Neoplasms/*genetics/pathology | 32 | 14.0 |
Carcinoma/*genetics/pathology | 2 | 3.0 |
*Gene Deletion | 11 | 1.0 |
Melanoma/*genetics | 3 | 2.0 |
Uveal Neoplasms/*genetics | 2 | 20.0 |
Epithelial Cells/metabolism/pathology | 3 | 6.0 |
Rats | 13 | 0.0 |
Repetitive Sequences, Amino Acid | 2 | 1.0 |
Sequence Homology, Amino Acid | 21 | 0.0 |
Adolescent | 25 | 0.0 |
Electrophoresis, Gel, Two-Dimensional | 2 | 0.0 |
Sequence Analysis, DNA | 18 | 0.0 |
Exons | 36 | 0.0 |
Genetic Heterogeneity | 4 | 1.0 |
Tumor Markers, Biological/*genetics | 8 | 7.0 |
BRCA1 Protein/*metabolism | 9 | 12.0 |
BRCA2 Protein/*metabolism | 10 | 100.0 |
Cell Cycle/physiology | 4 | 1.0 |
Cell Transformation, Neoplastic | 6 | 1.0 |
Chromosome Fragility | 2 | 3.0 |
DNA-Binding Proteins/metabolism | 9 | 0.0 |
Models, Biological | 14 | 0.0 |
Cohort Studies | 28 | 1.0 |
Costs and Cost Analysis | 2 | 3.0 |
United States | 13 | 1.0 |
Down-Regulation | 6 | 0.0 |
RNA, Messenger/metabolism | 7 | 0.0 |
Time Factors | 20 | 0.0 |
Macromolecular Substances | 5 | 0.0 |
Models, Molecular | 6 | 0.0 |
Protein Conformation | 5 | 0.0 |
Sequence Alignment | 7 | 0.0 |
Transcription Factors/genetics/*metabolism | 8 | 1.0 |
Transcription, Genetic | 20 | 0.0 |
Two-Hybrid System Techniques | 5 | 0.0 |
Carrier Proteins/*genetics | 2 | 0.0 |
Ovarian Neoplasms/diagnosis/*genetics | 4 | 33.0 |
Protein Structure, Tertiary/genetics | 2 | 0.0 |
*Tumor Suppressor Proteins | 14 | 1.0 |
*Ubiquitin-Protein Ligases | 4 | 0.0 |
Breast Neoplasms/genetics/prevention & control | 2 | 50.0 |
*Communication | 2 | 18.0 |
Motivation | 2 | 10.0 |
*Nuclear Family | 2 | 11.0 |
Ovarian Neoplasms/genetics/prevention & control | 2 | 50.0 |
Chromosome Breakage | 6 | 7.0 |
Dose-Response Relationship, Radiation | 6 | 1.0 |
*Haplotypes | 5 | 2.0 |
Head and Neck Neoplasms/*genetics | 3 | 4.0 |
Germany/epidemiology | 3 | 2.0 |
Haplotypes/genetics | 3 | 0.0 |
Ovarian Neoplasms/epidemiology/genetics | 12 | 57.0 |
RNA Splicing/genetics | 2 | 1.0 |
Sequence Deletion | 31 | 1.0 |
Cost-Benefit Analysis | 2 | 1.0 |
*Genetic Screening/economics | 2 | 50.0 |
CA-125 Antigen/blood | 2 | 6.0 |
Ovarian Neoplasms/*epidemiology/*genetics/prevention & control | 2 | 100.0 |
Australia | 8 | 4.0 |
Chromosomes, Human, Pair 13/*genetics | 24 | 32.0 |
Europe | 4 | 1.0 |
*Linkage (Genetics) | 4 | 0.0 |
North America | 3 | 5.0 |
BRCA2 Protein/genetics/*physiology | 2 | 100.0 |
Breast Neoplasms/genetics/psychology | 2 | 66.0 |
*Genetic Counseling | 12 | 25.0 |
Ethnic Groups/genetics | 3 | 1.0 |
Finland | 4 | 1.0 |
Geography | 4 | 6.0 |
Iceland | 6 | 15.0 |
Phylogeny | 3 | 0.0 |
Sequence Deletion/*genetics | 5 | 4.0 |
Cystadenocarcinoma, Papillary/*genetics | 2 | 66.0 |
Uterine Neoplasms/*genetics | 2 | 5.0 |
DNA, Neoplasm/*genetics | 4 | 1.0 |
Ovarian Neoplasms/*genetics/pathology | 6 | 7.0 |
Breast Neoplasms/*genetics/metabolism/pathology | 6 | 11.0 |
Neoplasm Proteins/metabolism | 3 | 0.0 |
Oligonucleotide Array Sequence Analysis/methods | 2 | 2.0 |
Hamsters | 4 | 0.0 |
Radiation Tolerance | 3 | 3.0 |
Sister Chromatid Exchange | 2 | 4.0 |
Greece | 2 | 2.0 |
Czech Republic | 2 | 4.0 |
DNA/chemistry/genetics | 3 | 0.0 |
Research Design | 5 | 5.0 |
Single-Blind Method | 3 | 1.0 |
Temperature | 3 | 0.0 |
Chromosomes, Human, Pair 11/genetics | 2 | 0.0 |
Repressor Proteins/*genetics | 2 | 0.0 |
*Chromosome Deletion | 13 | 1.0 |
*Point Mutation | 9 | 0.0 |
Models, Genetic | 27 | 1.0 |
Calcium-Binding Proteins/*genetics | 2 | 2.0 |
Cell Cycle/*genetics | 2 | 2.0 |
Green Fluorescent Proteins | 6 | 0.0 |
Chromosomes, Human/*genetics | 2 | 4.0 |
Genetic Markers/genetics | 21 | 4.0 |
Microsatellite Repeats/genetics | 12 | 3.0 |
Thyroid Neoplasms/*genetics | 2 | 2.0 |
Dogs | 3 | 0.0 |
Sequence Homology, Nucleic Acid | 5 | 0.0 |
Double-Blind Method | 3 | 0.0 |
BRCA1 Protein/genetics/*physiology | 5 | 38.0 |
Chromatin/metabolism | 6 | 2.0 |
DNA/metabolism | 6 | 0.0 |
Breast Neoplasms/epidemiology/*genetics/*prevention & control | 4 | 100.0 |
*Heterozygote | 22 | 6.0 |
*Mastectomy | 4 | 19.0 |
Life Style | 6 | 4.0 |
Radiation, Ionizing | 4 | 2.0 |
Antibodies | 2 | 0.0 |
BRCA2 Protein/*analysis | 2 | 100.0 |
Ovarian Neoplasms/etiology/*genetics | 4 | 44.0 |
Colorectal Neoplasms, Hereditary Nonpolyposis/genetics | 5 | 11.0 |
Clinical Trials | 4 | 0.0 |
Diet | 2 | 0.0 |
Exercise | 3 | 2.0 |
Magnetic Resonance Imaging | 2 | 0.0 |
*Mammography | 3 | 27.0 |
*Mass Screening | 4 | 7.0 |
Epidemiology, Molecular | 3 | 3.0 |
BRCA1 Protein/analysis/*genetics | 2 | 66.0 |
Feasibility Studies | 3 | 1.0 |
Gene Expression Regulation, Neoplastic/physiology | 3 | 2.0 |
Tumor Markers, Biological/analysis/*genetics | 2 | 9.0 |
Patient Satisfaction | 4 | 10.0 |
Quality of Life | 2 | 1.0 |
Stress, Psychological | 2 | 7.0 |
Neoplasms, Multiple Primary/*genetics | 6 | 15.0 |
BRCA2 Protein/*immunology/metabolism | 2 | 100.0 |
Epitopes | 2 | 0.0 |
Protein Binding | 18 | 0.0 |
*Chromosomes, Human, Pair 15 | 2 | 0.0 |
Nucleic Acid Hybridization | 8 | 0.0 |
Cluster Analysis | 6 | 3.0 |
Netherlands/epidemiology | 4 | 3.0 |
Polymorphism, Restriction Fragment Length | 5 | 0.0 |
BRCA2 Protein | 403 | 79.0 |
Transcription Factors/*genetics | 262 | 13.0 |
Child | 12 | 0.0 |
Ovarian Neoplasms/genetics/*pathology | 3 | 13.0 |
Fungal Proteins/*genetics | 2 | 1.0 |
Neoplasm Proteins/genetics | 72 | 15.0 |
Proto-Oncogene Proteins/genetics | 9 | 1.0 |
*Saccharomyces cerevisiae Proteins | 6 | 0.0 |
Breast Neoplasms/genetics/*psychology | 5 | 71.0 |
Socioeconomic Factors | 2 | 1.0 |
*Acid Anhydride Hydrolases | 4 | 1.0 |
Chromosomes, Human, Pair 13 | 10 | 7.0 |
*Chromosomes, Human, Pair 17 | 4 | 0.0 |
*Chromosomes, Human, Pair 3 | 2 | 0.0 |
*Chromosomes, Human, Pair 9 | 3 | 1.0 |
Protein p16/genetics | 2 | 2.0 |
Proteins/genetics | 7 | 0.0 |
Blotting, Southern | 7 | 0.0 |
Finland/epidemiology | 9 | 7.0 |
Genes, p53/genetics | 13 | 5.0 |
Mammary Neoplasms, Animal/*genetics | 2 | 28.0 |
*Mice, Knockout | 2 | 15.0 |
Protein-Serine-Threonine Kinases/genetics | 6 | 4.0 |
Variation (Genetics) | 8 | 0.0 |
Breast Neoplasms/*epidemiology/*genetics | 7 | 19.0 |
Child, Preschool | 8 | 0.0 |
Infant | 7 | 0.0 |
Transcription Factors/genetics | 74 | 8.0 |
Neoplastic Syndromes, Hereditary/genetics | 8 | 26.0 |
Odds Ratio | 19 | 1.0 |
Breast Neoplasms/drug therapy/*genetics/radiotherapy | 2 | 66.0 |
Genes, BRCA1/*genetics | 92 | 41.0 |
Genetic Markers/*genetics | 8 | 7.0 |
Breast/metabolism | 6 | 6.0 |
Carcinoma/genetics | 2 | 6.0 |
Genes, erbB-2/genetics | 3 | 11.0 |
RNA/metabolism | 3 | 0.0 |
Adenomatous Polyposis Coli/genetics | 3 | 10.0 |
Colorectal Neoplasms/genetics | 3 | 7.0 |
Neoplasms/*genetics | 16 | 6.0 |
*Primary Health Care | 2 | 20.0 |
Israel | 9 | 5.0 |
Drug Resistance, Neoplasm | 3 | 0.0 |
Mutagenesis, Site-Directed | 5 | 0.0 |
Neoplasm Proteins/*genetics/*metabolism | 3 | 17.0 |
Recombinant Proteins/metabolism | 3 | 0.0 |
Repetitive Sequences, Nucleic Acid | 7 | 0.0 |
Restriction Mapping | 2 | 0.0 |
Transcription Factors/*genetics/*metabolism | 3 | 2.0 |
Breast Neoplasms/epidemiology/*genetics/pathology | 5 | 62.0 |
Prostatic Neoplasms/genetics | 4 | 8.0 |
BRCA1 Protein/*physiology | 5 | 23.0 |
Carrier Proteins/genetics/metabolism | 2 | 1.0 |
Follow-Up Studies | 9 | 0.0 |
Receptor, erbB-2/analysis | 2 | 2.0 |
Decision Making | 10 | 14.0 |
Jews/*genetics | 42 | 28.0 |
Nuclear Family | 6 | 2.0 |
Practice Guidelines | 4 | 5.0 |
France/ethnology | 5 | 12.0 |
Protein-Serine-Threonine Kinases/*genetics | 14 | 4.0 |
Genes, Tumor Suppressor/*genetics | 31 | 10.0 |
*Population Surveillance | 2 | 5.0 |
DNA Methylation | 7 | 1.0 |
Genome | 3 | 1.0 |
Promoter Regions (Genetics) | 5 | 0.0 |
Penetrance | 15 | 12.0 |
Age Factors | 32 | 1.0 |
Chromosome Deletion | 4 | 0.0 |
Genes, Tumor Suppressor/genetics | 10 | 6.0 |
Genes, BRCA1/genetics | 39 | 57.0 |
*Genetic Predisposition to Disease/genetics | 3 | 42.0 |
*Practice Guidelines | 2 | 7.0 |
Disease Susceptibility | 24 | 3.0 |
Neoplasm Proteins/genetics/*metabolism | 9 | 4.0 |
Protein p53/metabolism | 8 | 1.0 |
Cell Differentiation | 5 | 0.0 |
Oncogenes | 4 | 1.0 |
Breast Neoplasms/*diagnosis/*genetics | 4 | 44.0 |
DNA-Binding Proteins/*metabolism | 7 | 0.0 |
S Phase/physiology | 2 | 2.0 |
Up-Regulation | 8 | 0.0 |
*BRCA2 Protein | 2 | 66.0 |
*Founder Effect | 23 | 18.0 |
Anxiety | 2 | 14.0 |
Depression | 2 | 18.0 |
Protein Kinases/*genetics | 4 | 3.0 |
*Protein-Serine-Threonine Kinases | 8 | 0.0 |
Canada/epidemiology | 4 | 10.0 |
Carcinoma, Ductal, Breast/epidemiology/*genetics/pathology | 2 | 100.0 |
Carcinoma, Lobular/epidemiology/*genetics/pathology | 2 | 100.0 |
Contig Mapping | 2 | 1.0 |
Linkage (Genetics)/*genetics | 4 | 1.0 |
DNA Mutational Analysis/*methods | 3 | 2.0 |
Electrophoresis, Capillary | 3 | 6.0 |
Heteroduplex Analysis | 4 | 5.0 |
Internet | 2 | 2.0 |
Netherlands | 4 | 2.0 |
*Recombination, Genetic | 14 | 4.0 |
Genes, Dominant/genetics | 2 | 1.0 |
Likelihood Functions | 9 | 5.0 |
Population Surveillance | 6 | 3.0 |
Chromosomes, Human, Pair 3/*genetics | 3 | 1.0 |
Genome, Human | 5 | 1.0 |
Cell Division | 16 | 0.0 |
Genes, BRCA1/*physiology | 9 | 27.0 |
Neoplasm Proteins/*physiology | 3 | 3.0 |
Transcription Factors/*physiology | 3 | 0.0 |
Carcinoma/*genetics | 10 | 9.0 |
Carcinoma, Squamous Cell/*genetics | 4 | 2.0 |
Esophageal Neoplasms/*genetics | 2 | 2.0 |
Survival Rate | 13 | 0.0 |
BRCA1 Protein/*biosynthesis | 5 | 45.0 |
Lymphatic Metastasis | 10 | 0.0 |
*Gene Expression Regulation/drug effects | 2 | 1.0 |
RNA, Messenger/genetics | 9 | 0.0 |
Stem Cells | 4 | 3.0 |
*Transcription, Genetic | 5 | 0.0 |
Apoptosis/genetics | 2 | 0.0 |
Chromosomes, Human, Pair 17/genetics | 7 | 4.0 |
Estrogens | 3 | 13.0 |
Neoplasms, Hormone-Dependent/genetics/pathology | 2 | 33.0 |
Prostatic Neoplasms/epidemiology/*genetics/pathology | 2 | 50.0 |
Trans-Activation (Genetics) | 4 | 0.0 |
*Adaptation, Psychological | 2 | 6.0 |
Carrier Proteins/genetics | 2 | 0.0 |
Point Mutation/genetics | 2 | 0.0 |
Ovarian Neoplasms/*genetics/prevention & control | 4 | 36.0 |
Research Design/standards | 2 | 22.0 |
BRCA2 Protein/genetics/*metabolism | 5 | 100.0 |
Recombinant Fusion Proteins/genetics/metabolism | 5 | 0.0 |
Ubiquitin/*metabolism | 2 | 1.0 |
European Continental Ancestry Group/genetics | 4 | 0.0 |
Neoplasms/genetics | 6 | 4.0 |
Molecular Biology | 4 | 1.0 |
*Mastectomy, Segmental | 3 | 42.0 |
*Heterozygote Detection | 5 | 4.0 |
Mammals | 3 | 0.0 |
Israel/epidemiology | 5 | 12.0 |
Multivariate Analysis | 8 | 0.0 |
Neoplasm Staging | 13 | 0.0 |
Survival Analysis | 14 | 0.0 |
*Transcription Factors | 2 | 0.0 |
Data Collection | 4 | 4.0 |
Breast Neoplasms/*ethnology/*genetics | 6 | 54.0 |
Genetic Predisposition to Disease/*ethnology | 3 | 25.0 |
Signal Transduction | 10 | 0.0 |
Cell Transformation, Neoplastic/*genetics | 3 | 1.0 |
Chromosome Aberrations/genetics | 3 | 2.0 |
Chromosome Disorders | 3 | 0.0 |
DNA Replication/genetics | 2 | 3.0 |
DNA-Binding Proteins/genetics/*metabolism | 2 | 0.0 |
Nuclear Proteins/*genetics | 4 | 0.0 |
Sweden | 2 | 0.0 |
Anticarcinogenic Agents/therapeutic use | 4 | 26.0 |
Breast Neoplasms, Male/epidemiology/genetics | 3 | 27.0 |
Ethics, Medical | 2 | 11.0 |
Breast Neoplasms/*genetics/radiotherapy/surgery | 2 | 100.0 |
Genes, BRCA2/*physiology | 6 | 54.0 |
Meiosis/*genetics | 2 | 5.0 |
Species Specificity | 3 | 0.0 |
*Cell Cycle Proteins | 10 | 0.0 |
Evolution, Molecular | 5 | 0.0 |
Neoplasm Proteins/*metabolism | 4 | 0.0 |
Nuclear Proteins/*genetics/*metabolism | 2 | 5.0 |
Recombinant Proteins/genetics/metabolism | 2 | 0.0 |
Transcription Factors/*metabolism | 4 | 0.0 |
Statistics, Nonparametric | 2 | 0.0 |
Cycloheximide/pharmacology | 3 | 0.0 |
Protein Synthesis Inhibitors/pharmacology | 2 | 0.0 |
Protein p53/*physiology | 2 | 1.0 |
Ultraviolet Rays | 5 | 0.0 |
Antineoplastic Agents/*pharmacology | 4 | 0.0 |
Cisplatin/pharmacology | 3 | 1.0 |
Doxorubicin/pharmacology | 4 | 1.0 |
Neoplasm Proteins/biosynthesis/*genetics | 4 | 4.0 |
Ovarian Neoplasms/*metabolism | 2 | 3.0 |
Paclitaxel/pharmacology | 2 | 2.0 |
RNA, Messenger/biosynthesis | 3 | 0.0 |
Transcription Factors/biosynthesis/*genetics | 3 | 2.0 |
Tumor Cells, Cultured/drug effects/radiation effects | 4 | 22.0 |
Arylamine N-Acetyltransferase/genetics | 3 | 5.0 |
Cytochrome P-450 CYP1A1/genetics | 3 | 3.0 |
Environmental Exposure | 2 | 1.0 |
Glutathione Transferase/genetics | 4 | 1.0 |
Menopause | 4 | 1.0 |
Ataxia Telangiectasia | 2 | 20.0 |
Phosphorylation | 7 | 0.0 |
Protein-Serine-Threonine Kinases/*metabolism | 2 | 0.0 |
Substrate Specificity | 4 | 0.0 |
Colorado | 2 | 13.0 |
*Family Practice | 2 | 33.0 |
*Physician's Practice Patterns | 2 | 11.0 |
Cell Cycle/genetics/*physiology | 2 | 10.0 |
DNA-Binding Proteins/genetics/metabolism | 5 | 1.0 |
Gene Expression | 12 | 0.0 |
Breast Neoplasms/epidemiology/genetics | 10 | 47.0 |
Iceland/epidemiology | 4 | 28.0 |
Mammography | 3 | 7.0 |
*Oncogenes | 8 | 1.0 |
Prostatic Neoplasms/epidemiology/genetics | 2 | 50.0 |
DNA Replication | 5 | 1.0 |
Neoplasm Proteins/genetics/*physiology | 6 | 12.0 |
Transcription Factors/genetics/*physiology | 6 | 3.0 |
Cyclin D1/analysis | 2 | 5.0 |
Genes, erbB-2 | 4 | 5.0 |
Receptors, Estrogen/analysis | 7 | 2.0 |
*Cell Transformation, Neoplastic | 3 | 0.0 |
Protein Kinases/genetics | 2 | 3.0 |
Colorectal Neoplasms/*genetics | 6 | 2.0 |
Genes, myc | 3 | 1.0 |
DNA, Neoplasm/genetics/metabolism | 3 | 3.0 |
Transcription Factors/metabolism | 2 | 0.0 |
Electrophoresis/methods | 3 | 3.0 |
Fluorescence | 3 | 1.0 |
*Chromosome Aberrations | 6 | 1.0 |
Active Transport, Cell Nucleus | 2 | 0.0 |
Binding Sites | 15 | 0.0 |
DNA/genetics/metabolism | 2 | 0.0 |
Microscopy, Electron | 2 | 0.0 |
Molecular Weight | 3 | 0.0 |
Neoplasm Proteins/chemistry/genetics/*metabolism | 2 | 9.0 |
Transcription Factors/chemistry/genetics/*metabolism | 2 | 1.0 |
DNA Damage/genetics | 3 | 7.0 |
Genes, Reporter | 2 | 0.0 |
Sequence Deletion/genetics | 2 | 1.0 |
*Sequence Homology, Nucleic Acid | 2 | 2.0 |
Forecasting | 3 | 0.0 |
*Models, Statistical | 3 | 4.0 |
Breast Neoplasms/*genetics/mortality/pathology | 3 | 37.0 |
Gene Frequency/genetics | 10 | 2.0 |
Tumor Markers, Biological/genetics | 2 | 2.0 |
BRCA1 Protein/*deficiency | 2 | 66.0 |
Enzyme Inhibitors/pharmacology | 3 | 0.0 |
Pancreatic Neoplasms/genetics/metabolism | 2 | 50.0 |
Breast Neoplasms/diagnosis/epidemiology/*genetics | 2 | 40.0 |
Haplotypes | 13 | 0.0 |
Introns | 9 | 0.0 |
Polymorphism, Single Nucleotide | 2 | 0.0 |
Variation (Genetics)/*genetics | 2 | 0.0 |
In Situ Hybridization | 4 | 0.0 |
Breast Neoplasms, Male/*genetics | 24 | 85.0 |
Genetics, Population | 7 | 1.0 |
Epidemiologic Studies | 2 | 4.0 |
Computer Simulation | 2 | 0.0 |
*Genes, Dominant | 2 | 0.0 |
Infant, Newborn | 3 | 0.0 |
Ontario | 3 | 13.0 |
Computational Biology/methods | 2 | 6.0 |
*Variation (Genetics) | 9 | 0.0 |
S Phase | 6 | 1.0 |
Codon | 6 | 1.0 |
Genetic Counseling/*psychology | 3 | 50.0 |
Ovarian Neoplasms/genetics/*psychology | 3 | 60.0 |
*Jews | 7 | 16.0 |
Poland/epidemiology | 2 | 3.0 |
Breast Neoplasms/genetics/*prevention & control | 5 | 45.0 |
Breast Neoplasms/enzymology/genetics | 3 | 17.0 |
Neoplasm Proteins/deficiency/*genetics | 4 | 44.0 |
Pancreatic Neoplasms/enzymology/genetics | 2 | 66.0 |
Transcription Factors/deficiency/*genetics | 4 | 40.0 |
Bioethics | 2 | 33.0 |
Ovarian Neoplasms/*epidemiology/*genetics | 3 | 50.0 |
Syndrome | 9 | 0.0 |
Apoptosis/drug effects | 2 | 0.0 |
Cell Line, Transformed | 5 | 0.0 |
Health Knowledge, Attitudes, Practice | 5 | 15.0 |
Breast Neoplasms/*diagnosis/genetics/psychology | 2 | 50.0 |
Communication | 3 | 15.0 |
Breast Neoplasms/epidemiology/genetics/*prevention & control | 2 | 33.0 |
Europe/epidemiology | 4 | 4.0 |
Cell Cycle Proteins/metabolism | 3 | 0.0 |
Cross-Linking Reagents/pharmacology | 4 | 2.0 |
Fanconi Anemia/*metabolism | 2 | 16.0 |
Nuclear Proteins/physiology | 3 | 3.0 |
Ubiquitin/metabolism | 3 | 1.0 |
Crystallography, X-Ray | 7 | 0.0 |
DNA-Binding Proteins/physiology | 2 | 0.0 |
DNA/*metabolism | 2 | 0.0 |
Attitude to Health | 4 | 9.0 |
Patient Compliance | 2 | 1.0 |
Evaluation Studies | 4 | 0.0 |
Genetic Screening/psychology | 3 | 60.0 |
Analysis of Variance | 2 | 0.0 |
Neoplasm Staging/methods | 2 | 6.0 |
Apoptosis | 6 | 0.0 |
Europe/ethnology | 6 | 6.0 |
*Questionnaires | 2 | 5.0 |
Sex Factors | 2 | 0.0 |
*Sex Ratio | 3 | 30.0 |
*Apoptosis | 2 | 0.0 |
Breast Neoplasms/epidemiology/etiology/*genetics | 2 | 28.0 |
Neoplasm Proteins/*genetics/metabolism | 7 | 4.0 |
Transcription Factors/*genetics/metabolism | 7 | 2.0 |
Steroid 17-alpha-Hydroxylase/*genetics | 2 | 6.0 |
DNA Repair/genetics/*physiology | 3 | 13.0 |
Genetic Vectors | 3 | 0.0 |
Neoplasm Proteins/deficiency/genetics/*physiology | 2 | 40.0 |
Oxidative Stress | 2 | 0.0 |
Transcription Factors/deficiency/genetics/*physiology | 2 | 11.0 |
BRCA1 Protein/analysis/genetics | 3 | 60.0 |
Cheek | 2 | 7.0 |
Neoplasm Proteins/analysis/*genetics | 4 | 12.0 |
Transcription Factors/analysis/*genetics | 3 | 9.0 |
African Continental Ancestry Group/*genetics | 2 | 0.0 |
Breast Neoplasms/blood/*genetics/pathology | 2 | 66.0 |
*Chromosomes, Human, Pair 8 | 2 | 0.0 |
DNA/blood | 4 | 2.0 |
Carcinoma in Situ/genetics/pathology | 2 | 28.0 |
Carcinoma, Ductal, Breast/genetics/pathology | 5 | 45.0 |
Cell Nucleus/pathology | 2 | 2.0 |
Receptors, Progesterone/analysis | 4 | 1.0 |
Neoplasm Proteins/analysis/genetics | 3 | 12.0 |
Transcription Factors/analysis/genetics | 3 | 21.0 |
Enzyme Activation | 2 | 0.0 |
JNK Mitogen-Activated Protein Kinases | 2 | 0.0 |
Genetic Techniques | 2 | 2.0 |
Prostatic Neoplasms/*genetics | 13 | 7.0 |
DNA, Neoplasm/blood/genetics | 4 | 40.0 |
*Pregnancy | 2 | 1.0 |
Blotting, Northern | 6 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 3 | 0.0 |
Mutagenesis | 4 | 0.0 |
Point Mutation | 11 | 0.0 |
*Promoter Regions (Genetics) | 3 | 0.0 |
Breast Neoplasms/*genetics/*prevention & control/therapy | 2 | 100.0 |
Primary Prevention/*methods | 3 | 33.0 |
Polymorphism, Genetic/genetics | 5 | 0.0 |
Cell Survival/drug effects/radiation effects | 3 | 7.0 |
Receptors, Transforming Growth Factor beta/genetics | 4 | 7.0 |
Carcinoma, Ductal, Breast/genetics | 2 | 11.0 |
Alcohol Drinking/adverse effects | 2 | 4.0 |
Food Habits | 2 | 7.0 |
Radiotherapy/adverse effects | 2 | 5.0 |
Breast Neoplasms/*genetics/mortality | 2 | 40.0 |
*Ovariectomy | 4 | 9.0 |
Algorithms | 3 | 0.0 |
Parity | 3 | 2.0 |
DNA Damage/*genetics | 3 | 5.0 |
Proto-Oncogenes/genetics | 2 | 6.0 |
Smoking/adverse effects | 3 | 1.0 |
China | 2 | 0.0 |
Genetic Screening/*utilization | 3 | 100.0 |
North Carolina | 2 | 8.0 |
Ovarian Neoplasms/genetics/*prevention & control | 2 | 25.0 |
Pilot Projects | 3 | 0.0 |
Databases, Factual | 2 | 0.0 |
*Alleles | 8 | 0.0 |
Gene Dosage | 3 | 0.0 |
Breast Neoplasms/diagnosis/genetics/*psychology | 2 | 50.0 |
Neoplasm Invasiveness | 7 | 0.0 |
*Frameshift Mutation | 6 | 3.0 |
Mutagenesis, Insertional | 2 | 0.0 |
Disease Models, Animal | 4 | 0.0 |
*Attitude to Health | 4 | 12.0 |
Breast Neoplasms/chemistry/*genetics | 3 | 16.0 |
Neoplasm Proteins/*analysis/genetics | 2 | 4.0 |
Transcription Factors/*analysis/genetics | 2 | 12.0 |
Acute Disease | 3 | 0.0 |
Fanconi Anemia/*complications/genetics/therapy | 2 | 100.0 |
Gene Therapy | 2 | 0.0 |
Histocompatibility Testing | 2 | 0.0 |
Leukemia, Myeloid/*complications/genetics/therapy | 2 | 100.0 |
Stem Cell Transplantation | 3 | 7.0 |
Poland | 5 | 3.0 |
Ploidies | 3 | 1.0 |
Counseling | 3 | 13.0 |
Mice, SCID | 3 | 0.0 |
Carcinoma, Lobular/genetics/pathology | 2 | 40.0 |
Carcinoma, Medullary/genetics/pathology | 2 | 50.0 |
Mitotic Index | 3 | 1.0 |
North America/epidemiology | 2 | 14.0 |
Luminescent Proteins | 2 | 3.0 |
Fathers | 2 | 3.0 |
Cell Transformation, Neoplastic/genetics | 6 | 2.0 |
Prostatic Neoplasms/epidemiology/*genetics | 2 | 15.0 |
*DNA Replication | 3 | 1.0 |
Chromosomes, Artificial, Yeast | 2 | 0.0 |
Chromosomes, Human, Pair 13/*genetics/ultrastructure | 2 | 33.0 |
Genes, Retinoblastoma | 3 | 3.0 |
Conserved Sequence/genetics | 2 | 1.0 |
Mutation, Missense/*genetics | 2 | 1.0 |
Mice, Nude | 2 | 0.0 |
Codon/genetics | 2 | 0.0 |
Confidence Intervals | 2 | 0.0 |
Frameshift Mutation/genetics | 6 | 7.0 |
Mutation, Missense/genetics | 3 | 1.0 |
Breast Neoplasms, Male/genetics/metabolism/pathology | 2 | 66.0 |
Linkage (Genetics)/genetics | 3 | 1.0 |
Neoplasms, Glandular and Epithelial/*genetics | 3 | 27.0 |
DNA, Complementary/genetics/isolation & purification | 2 | 1.0 |
Drosophila/genetics | 2 | 1.0 |
*Drosophila Proteins | 3 | 0.0 |
Adenocarcinoma/*genetics | 5 | 3.0 |
Protein p16/*genetics | 3 | 3.0 |
Alcohol Drinking | 3 | 2.0 |
Poisson Distribution | 2 | 9.0 |
Smoking | 4 | 1.0 |
Mastectomy/methods | 3 | 60.0 |
Italy | 7 | 1.0 |
Cell Cycle/genetics | 3 | 2.0 |
Chromatography, High Pressure Liquid/*methods | 2 | 1.0 |
Hydrogen Bonding | 2 | 1.0 |
*Risk | 3 | 33.0 |
Frameshift Mutation/*genetics | 2 | 3.0 |
Health Personnel/*education | 2 | 22.0 |
Gene Expression Regulation, Developmental | 2 | 0.0 |
Saccharomyces cerevisiae/genetics | 5 | 1.0 |
Breast Neoplasms, Male/diagnosis/*genetics | 2 | 100.0 |
Codon, Nonsense/genetics | 2 | 3.0 |
Germany | 4 | 1.0 |
Proteins/*genetics | 6 | 0.0 |
*Family | 4 | 10.0 |
Radiotherapy Dosage | 3 | 2.0 |
Consensus Sequence | 4 | 0.0 |
Colorectal Neoplasms, Hereditary Nonpolyposis/*genetics | 3 | 3.0 |
Microsatellite Repeats/*genetics | 3 | 1.0 |
*Multidrug Resistance-Associated Proteins | 2 | 3.0 |
*Proto-Oncogene Proteins c-bcl-2 | 3 | 0.0 |
Receptor, IGF Type 2/genetics | 2 | 8.0 |
DNA, Neoplasm | 4 | 3.0 |
Cystic Fibrosis/genetics | 2 | 6.0 |
Gaucher Disease/genetics | 2 | 28.0 |
Genetic Diseases, Inborn/*genetics | 2 | 3.0 |
*Decision Making | 2 | 22.0 |
*Decision Support Techniques | 3 | 20.0 |
Matched-Pair Analysis | 3 | 3.0 |
Neoplasms/epidemiology/genetics | 2 | 66.0 |
Introns/genetics | 2 | 0.0 |
Carcinoma, Ductal, Breast/*genetics/pathology | 5 | 19.0 |
Gene Expression Regulation, Neoplastic/*genetics | 2 | 1.0 |
Neoplasm Invasiveness/genetics | 3 | 6.0 |
Ataxia Telangiectasia/*genetics | 3 | 4.0 |
DNA/genetics | 3 | 0.0 |
Kidney Neoplasms/genetics | 3 | 4.0 |
Lymphocytes/radiation effects | 2 | 18.0 |
Cytoplasm/metabolism | 2 | 0.0 |
Promoter Regions (Genetics)/*genetics | 3 | 0.0 |
DNA-Binding Proteins/*genetics/metabolism | 3 | 0.0 |
G2 Phase | 3 | 1.0 |
Microscopy, Fluorescence | 3 | 0.0 |
*Centrosome | 2 | 25.0 |
DNA, Satellite | 2 | 7.0 |
Gene Amplification | 4 | 0.0 |
*Genome | 2 | 1.0 |
*Disease Models, Animal | 2 | 0.0 |
Mice, Transgenic | 3 | 0.0 |
Neoplasms/*genetics/*pathology | 2 | 25.0 |
Pregnancy | 6 | 0.0 |
Cell Nucleus/ultrastructure | 2 | 1.0 |
RNA, Neoplasm/genetics | 2 | 0.0 |
Polymorphism, Genetic/*genetics | 3 | 0.0 |
DNA, Neoplasm/analysis/genetics | 2 | 2.0 |
DNA Primers/genetics | 4 | 0.0 |
*Family Health | 3 | 5.0 |
Fungal Proteins/genetics | 2 | 1.0 |
DNA Repair/genetics | 6 | 3.0 |
Trans-Activation (Genetics)/*genetics | 2 | 2.0 |
Breast Neoplasms/genetics/pathology | 4 | 11.0 |
COS Cells | 2 | 0.0 |
Interphase | 4 | 2.0 |
Neoplasms/ethnology/*genetics | 2 | 66.0 |
Nuclear Proteins/*metabolism | 4 | 0.0 |
Carcinoma/genetics/pathology | 2 | 9.0 |
Chromosome Mapping/*methods | 2 | 1.0 |
Chromosomes, Human, Pair 12/*genetics | 2 | 1.0 |
Breast Neoplasms/genetics/*metabolism | 2 | 3.0 |
*Conserved Sequence | 2 | 1.0 |
Proteins/genetics/*metabolism | 2 | 0.0 |
Rabbits | 3 | 0.0 |
Tumor Cells, Cultured/radiation effects | 2 | 5.0 |
BRCA1 Protein/*genetics/physiology | 2 | 33.0 |
Neoplasm Proteins/*genetics/physiology | 3 | 14.0 |
Transcription Factors/*genetics/physiology | 3 | 3.0 |
Receptors, Estrogen/metabolism | 6 | 2.0 |
Receptors, Progesterone/metabolism | 6 | 3.0 |
Adenocarcinoma/genetics/pathology | 3 | 7.0 |
Lymphoma/*genetics | 2 | 4.0 |
Chromosomes, Human, Pair 8 | 2 | 1.0 |
*Cell Cycle | 4 | 1.0 |
Growth Substances/*biosynthesis | 2 | 4.0 |
*Genes, BRCA1/physiology | 2 | 66.0 |
Breast Neoplasms/diagnosis/*genetics/prevention & control | 2 | 100.0 |
Gene Expression Regulation, Neoplastic/*drug effects | 4 | 1.0 |
Prostatic Neoplasms/*genetics/pathology | 3 | 3.0 |
Cyclins/genetics | 3 | 2.0 |
Embryo/cytology | 2 | 2.0 |
Protein p53/*genetics | 2 | 1.0 |
Ovarian Neoplasms/*genetics/*prevention & control | 4 | 66.0 |
Nocodazole/pharmacology | 3 | 2.0 |
Breast Neoplasms/*genetics/pathology/*therapy | 2 | 50.0 |
Nutrition | 2 | 5.0 |
Spain/ethnology | 2 | 6.0 |
District of Columbia/epidemiology | 2 | 22.0 |
Risk Assessment/statistics & numerical data | 2 | 40.0 |
Belgium | 2 | 3.0 |
DNA Transposable Elements | 2 | 1.0 |
Lymphocytes/chemistry | 2 | 3.0 |
Estrogen Antagonists/therapeutic use | 2 | 16.0 |
Genetic Screening/methods/statistics & numerical data | 2 | 50.0 |
Receptors, Androgen/genetics | 2 | 3.0 |
Contraceptives, Oral/adverse effects | 2 | 18.0 |
Organ Specificity | 5 | 0.0 |
Ovarian Neoplasms/genetics/pathology | 2 | 14.0 |
Teaching Materials | 2 | 18.0 |
Immunohistochemistry/methods | 2 | 0.0 |
Proteins/metabolism | 3 | 0.0 |
Receptors, Estrogen/*metabolism | 4 | 1.0 |
*Chemoprevention | 2 | 28.0 |
Neoplasm Transplantation | 2 | 0.0 |
Metaphase | 2 | 1.0 |
*Microsatellite Repeats | 3 | 1.0 |
Carcinoma, Ductal, Breast/*genetics | 3 | 12.0 |
Hamartoma Syndrome, Multiple/*genetics | 2 | 6.0 |
Phosphoric Monoester Hydrolases/*genetics | 2 | 0.0 |
Breast Neoplasms/ethnology/*genetics/*psychology | 2 | 100.0 |
Acetyltransferases/*metabolism | 2 | 2.0 |
Antibodies, Monoclonal | 3 | 0.0 |
Breast Neoplasms/metabolism | 2 | 1.0 |
RNA, Messenger/analysis/metabolism | 2 | 1.0 |
Chromosomal Instability/*genetics | 2 | 40.0 |
Colorectal Neoplasms/genetics/pathology | 2 | 11.0 |
Karyotyping | 4 | 0.0 |
Pancreatic Neoplasms/genetics/pathology | 2 | 25.0 |
BRCA1 Protein/physiology | 4 | 26.0 |
BRCA2 Protein/physiology | 2 | 66.0 |
Neoplasms, Second Primary/*genetics | 2 | 9.0 |
Breast Neoplasms/complications/*genetics | 3 | 60.0 |
Ovarian Neoplasms/complications/*genetics | 2 | 50.0 |
Breast Neoplasms/*genetics/psychology | 2 | 22.0 |
Patient Care Team | 2 | 11.0 |
Protein p53/analysis | 2 | 0.0 |
Tumor Markers, Biological | 3 | 0.0 |
Chromosomes, Human, Pair 17 | 7 | 2.0 |
*Chromosome Mapping | 3 | 0.0 |
Chromosomes, Human | 2 | 3.0 |
BRCA1 Protein/genetics/*metabolism | 2 | 5.0 |
Data Interpretation, Statistical | 3 | 1.0 |
Loss of Heterozygosity/genetics | 2 | 1.0 |
Stilbenes/*pharmacology | 2 | 3.0 |
*Phosphoric Monoester Hydrolases | 2 | 4.0 |
Contraceptives, Oral/*therapeutic use | 2 | 28.0 |
Ovarian Neoplasms/epidemiology/genetics/*prevention & control | 2 | 40.0 |
Plant Proteins/genetics | 2 | 14.0 |
Oncogenes/genetics | 4 | 5.0 |
Genes, Retinoblastoma/*genetics | 2 | 4.0 |
Antineoplastic Agents/pharmacology | 2 | 0.0 |
DNA, Neoplasm/*analysis | 3 | 1.0 |
Breast Neoplasms/*genetics/*prevention & control | 6 | 46.0 |
Government Regulation | 2 | 100.0 |
Women's Health | 2 | 5.0 |
Lymph Nodes/pathology | 2 | 0.0 |
Cell Transformation, Neoplastic/genetics/pathology | 2 | 9.0 |
*Proto-Oncogene Proteins | 2 | 0.0 |
Scotland | 2 | 5.0 |
*Gene Therapy | 2 | 0.0 |
Gene Transfer Techniques | 2 | 0.0 |
Multiple Endocrine Neoplasia Type 2a/genetics | 2 | 6.0 |
Receptor Protein-Tyrosine Kinases/genetics | 2 | 1.0 |
DNA, Complementary/genetics | 8 | 0.0 |
Great Britain | 4 | 1.0 |
Chickens | 3 | 0.0 |
Models, Statistical | 3 | 1.0 |
*Genetic Heterogeneity | 3 | 2.0 |
*Pedigree | 3 | 10.0 |
*DNA Methylation | 2 | 0.0 |
Saccharomyces cerevisiae | 3 | 1.0 |
African Continental Ancestry Group/genetics | 2 | 0.0 |
Ovarian Neoplasms/ethnology/genetics | 2 | 50.0 |
Korea | 2 | 0.0 |
DNA/blood/genetics | 2 | 3.0 |
Breast Self-Examination | 3 | 60.0 |
Leukemia, Lymphocytic, Chronic/*genetics | 3 | 13.0 |
District of Columbia | 3 | 30.0 |
Polymorphism, Single Nucleotide/*genetics | 2 | 0.0 |
Tissue Distribution | 2 | 0.0 |
Chromosomes, Human, Pair 11/*genetics | 2 | 0.0 |
BRCA2 Protein/chemistry/*metabolism | 2 | 100.0 |
DNA, Single-Stranded/*metabolism | 2 | 7.0 |
Breast Neoplasms/ethnology/genetics | 2 | 40.0 |
Sex Distribution | 3 | 1.0 |
Electrophoresis, Agar Gel | 3 | 0.0 |
Flow Cytometry | 4 | 0.0 |
Causality | 3 | 7.0 |
*Genetics, Population | 3 | 0.0 |
World Health | 2 | 3.0 |
Cell Division/physiology | 2 | 0.0 |
DNA-Binding Proteins/*physiology | 2 | 0.0 |
Lymphatic Metastasis/diagnosis/genetics | 2 | 100.0 |
DNA, Satellite/genetics | 2 | 1.0 |
Carcinoma, Hepatocellular/*genetics | 2 | 2.0 |
Liver Neoplasms/*genetics | 2 | 1.0 |
Retinoblastoma Protein/genetics | 3 | 8.0 |
BRCA1 Protein | 16 | 15.0 |
Pseudogenes/genetics | 2 | 2.0 |
*Genes, Retinoblastoma | 5 | 4.0 |
Pancreatic Neoplasms/genetics | 2 | 5.0 |
DNA, Neoplasm/genetics/isolation & purification | 2 | 1.0 |
Carcinoma/pathology | 2 | 4.0 |
Proto-Oncogenes | 2 | 1.0 |
Carcinoma, Lobular/*genetics | 2 | 28.0 |
Program Evaluation | 2 | 4.0 |
Breast Neoplasms, Male/genetics/pathology | 2 | 40.0 |
Neoplasms/*genetics/pathology | 2 | 5.0 |
BRCA2 Protein/*biosynthesis | 2 | 100.0 |
DNA/analysis | 2 | 0.0 |
Anxiety/etiology | 2 | 33.0 |
*Gene Rearrangement | 3 | 1.0 |
Polymerase Chain Reaction/*methods | 3 | 0.0 |
Alternative Splicing/genetics | 4 | 2.0 |
India | 3 | 0.0 |
RNA, Small Interfering/metabolism | 2 | 1.0 |
Binding Sites/genetics | 2 | 0.0 |
*Mutation, Missense | 3 | 0.0 |
*Genetic Predisposition to Disease/*epidemiology | 2 | 66.0 |
Ovarian Neoplasms/*genetics/*pathology | 2 | 22.0 |
*Registries | 2 | 4.0 |
Cell Death | 2 | 0.0 |
BRCA2 Protein/deficiency/*genetics | 2 | 100.0 |
Fetal Death/genetics | 2 | 9.0 |
Carcinoma/*genetics/metabolism | 2 | 6.0 |
Gene Amplification/genetics | 2 | 3.0 |
Gene Silencing/physiology | 2 | 8.0 |
Genes, Regulator/genetics | 2 | 4.0 |
*Nuclear Proteins | 4 | 0.0 |
*Mitosis | 2 | 1.0 |
BRCA2 Protein/analysis/genetics | 2 | 100.0 |
Bloom Syndrome/genetics | 2 | 15.0 |
Recombination, Genetic/*genetics | 2 | 2.0 |
Receptors, Androgen/*metabolism | 2 | 1.0 |
Chromosome Segregation | 2 | 5.0 |
Protein Structure, Secondary | 3 | 0.0 |
Fanconi Anemia/*genetics/metabolism | 2 | 25.0 |
DNA-Binding Proteins/*chemistry/genetics/*metabolism | 2 | 3.0 |
Plasmids/metabolism | 3 | 0.0 |
DNA Damage/drug effects | 2 | 4.0 |
DNA, Complementary/metabolism | 3 | 0.0 |
Luminescent Proteins/metabolism | 2 | 0.0 |
Chile | 3 | 5.0 |
Spouses/*psychology | 2 | 100.0 |
Gene Rearrangement/*genetics | 2 | 5.0 |
RNA Splice Sites/*genetics | 2 | 5.0 |
Protein p53/genetics/metabolism | 2 | 2.0 |
BRCA2 Protein/*chemistry/*metabolism | 2 | 100.0 |
Fanconi Anemia/genetics | 2 | 16.0 |
BRCA2 Protein/*chemistry/genetics/*metabolism | 3 | 100.0 |
DNA, Single-Stranded/metabolism | 3 | 4.0 |
RNA Splice Sites/genetics | 2 | 1.0 |
Hydrophobicity | 2 | 2.0 |
Consanguinity | 2 | 0.0 |
Protein Folding | 2 | 0.0 |
Health Surveys | 2 | 2.0 |
Pancreatic Neoplasms/epidemiology/*genetics | 2 | 28.0 |
